A catalog of numerical centrosome defects in epithelial ovarian cancers
Jean‐Philippe Morretton, Anthony Simon, Aurélie Herbette, Jorge Barbazán, Carlos Pérez‐González, Camille Cosson, Bassirou Mboup, Aurélien Latouche, Tatiana Popova, Yann Kieffer, Anne‐Sophie Macé, Pierre Gestraud, Guillaume Bataillon, Véronique Becette, Didier Meseure, Nicolás André, Odette Mariani, Anne Vincent‐Salomon, Marc‐Henri Stern, Fatima Mechta‐Grigoriou, Sergio Roman‐Roman, Danijela Matic Vignjevic, Roman Rouzier, Xavier Sastre‐Garau, Oumou Goundiam, Renata Basto
Abstract
Centrosome amplification, the presence of more than two centrosomes in a cell is a common feature of most human cancer cell lines. However, little is known about centrosome numbers in human cancers and whether amplification or other numerical aberrations are frequently present. To address this question, we have analyzed a large cohort of primary human epithelial ovarian cancers (EOCs) from 100 patients. We found that rigorous quantitation of centrosome number in tumor samples was extremely challenging due to tumor heterogeneity and extensive tissue disorganization. Interestingly, even if centrosome clusters could be identified, the incidence of centrosome amplification was not comparable to what has been described in cultured cancer cells. Surprisingly, centrosome loss events where a few or many nuclei were not associated with centrosomes were clearly noticed and overall more frequent than centrosome amplification. Our findings highlight the difficulty of characterizing centrosome numbers in human tumors, while revealing a novel paradigm of centrosome number defects in EOCs. Characterization of the centrosome number in epithelial ovarian cancers (EOCs) is challenging because these tumors are extremely disorganized and heterogeneous in respect to centrosome number. Characterization of the centrosome number in epithelial ovarian cancers (EOCs) is challenging because these tumors are extremely disorganized and heterogeneous in respect to centrosome number.